Aripiprazole Tablet
Product Images NDC 50268-090

18 FDA label images from Avpak · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50268-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Table 2)

1 (Table 2)
This data table presents dosage adjustments for Aripiprazole tablets based on different metabolic factors. It lists adjustments for poor metabolizers of CYP2D6, those taking strong CYP3A4 inhibitors, and those taking CYP3A4 inducers, specifying how dose proportions should be altered accordingly.*
FDA Label Image

Formula (Screen Shot 2016 04 28 At 11.33.28 Am)

Formula (Screen Shot 2016 04 28 At 11.33.28 Am)
Chemical structure of Aripiprazole showing its molecular configuration, including chlorinated aromatic rings and nitrogen-containing heterocycles.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A graph titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax. It compares changes relative to a reference without interacting drugs for various inhibitors, inducers, gastric acid blockers, and other drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence intervals of dehydro-aripiprazole pharmacokinetics parameters (AUC and Cmax) relative to a reference without interacting drugs. The graph compares the effects of CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs including valproate, lithium, and lorazepam on Aripiprazole exposure.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
A forest plot chart showing the effect of Aripiprazole on pharmacokinetic parameters of various drugs. The chart plots fold change and 90% confidence intervals for metrics such as AUC, Cmax, DMDRP, and INR relative to a reference without interacting drug, for drugs including dextromethorphan, S-warfarin, R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and O-desmethylvenlafaxine.*
FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
A forest plot chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic comparisons of Aripiprazole in special populations. Variables include CYP2D6 poor vs. extensive metabolizers, gender, age groups, hepatic impairment (mild, moderate, severe), and severe renal impairment. The chart plots fold changes in AUC and Cmax with 90% confidence intervals relative to reference populations.*
FDA Label Image

Figure5 (Figure5)

Figure5 (Figure5)
A chart illustrating the fold change and 90% confidence interval for dehydro-aripiprazole pharmacokinetics (AUC and Cmax) across various factors: CYP2D6 metabolizer status, gender, age groups, hepatic impairment severities, and severe renal impairment. The x-axis represents change relative to reference from 0.5 to 3.0.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A line graph comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The graph includes a table below indicating the number of subjects at risk at various time points for both groups.*
FDA Label Image

1 (Figure 7)

1 (Figure 7)
A Kaplan-Meier curve illustrating the cumulative proportion of patients with relapse over 182 days from randomization in a Bipolar Study 7. The graph compares Aripiprazole (solid blue line) versus placebo (dashed red line), with the y-axis showing proportion with relapse and the x-axis showing days from randomization. Below the graph is a table showing the number of subjects at risk for each treatment group across time points.*
FDA Label Image

1 (Figure 8)

1 (Figure 8)
A Kaplan-Meier estimation chart showing the cumulative proportion of patients with relapse to any mood event over 364 days. The graph compares two groups: patients treated with Aripiprazole and a placebo group, with proportion with relapse on the vertical axis and days from randomization on the horizontal axis. The chart includes subject numbers at risk for both groups across the timeline.*
FDA Label Image

1 (Figure 9)

1 (Figure 9)
A line graph depicting the least squares mean change from baseline in YGTSS total tic score over weeks of treatment from 0 to 8 weeks. The graph compares three groups: Abilify Low, Abilify High, and Placebo, showing a decrease in tic scores over time, with Abilify High showing the greatest reduction followed by Abilify Low, and the Placebo group showing the least change.*
FDA Label Image

1 (Table 30)

1 (Table 30)
A data table titled 'Tourette's Disorder Studies (Pediatric)' presenting clinical study results for Aripiprazole tablets versus placebo. The table includes columns for study number, treatment groups (low and high doses of Aripiprazole tablets, and placebo), mean baseline scores, least squares mean changes from baseline, and placebo-subtracted differences with 95% confidence intervals measuring efficacy using the YGTSS TTS scale.*
FDA Label Image

1 (087 12)

1 (087 12)
Label for Aripiprazole Tablets, USP 2 mg oral tablets, supplied in unit dose packaging containing 20 tablets (2 x 10). The label includes the NDC 50268-087-12, states Rx only, and provides storage instructions and a pharmacist note about dispensing the Medication Guide. Manufactured by AvPAK, AvKARE, Pulaski, TN.*
FDA Label Image

1 (088 15)

1 (088 15)
Label for Aripiprazole Tablets USP 5 mg by AvPAK, presenting 50 tablets as unit dose packaging (5 x 10). It includes the NDC 50268-088-15, barcode, storage instructions, and a pharmacist note to dispense the medication guide separately.*
FDA Label Image

1 (089 15)

1 (089 15)
Packaging label for Aripiprazole Tablets, USP 10 mg oral tablets by AvPAK. The label shows the NDC 50268-089-15, states 'Rx Only,' and indicates a supply of 50 tablets (5 x 10 unit dose). Additional instructions include pharmacist guidance to dispense the Medication Guide and storage conditions.*
FDA Label Image

1 (090 12)

1 (090 12)
Aripiprazole Tablets USP 15 mg oral tablets label. The label shows a package of 20 tablets (2 x 10) in unit dose form, marked Rx Only. The label includes storage instructions, a barcode, and manufacturer AvPAK information. The label emphasizes pharmacist dispensing the medication guide separately.*
FDA Label Image

1 (091 12)

1 (091 12)
Packaging label for Aripiprazole Tablets USP, 20 mg strength, oral tablet dosage form. The label indicates a 20 tablet count (2 x 10 unit dose) and states prescription-only status. It includes storage instructions, a barcode, and manufacturer information for AvPAK, Pulaski, TN. The label also contains a pharmacist dispensing instruction regarding the Medication Guide.*
FDA Label Image

1 (092 12)

1 (092 12)
The image shows a medication label for Aripiprazole Tablets, USP, 30 mg oral tablets. The label indicates a package containing 20 tablets (2 x 10) in unit dose format. It is labeled Rx Only and includes storage instructions of 20° to 25°C. Manufactured for AvPAK in Pulaski, TN, the label features the AvPAK logo and barcode, along with a pharmacist instruction to dispense the Medication Guide separately to each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.